Honigman Advises Helius Medical Technologies Over $500 Million PIPE to Launch SOL Digital Asset Treasury Strategy

Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced the pricing of an oversubscribed private investment in public equity offering for shares of common stock (and/or pre-funded warrants to purchase shares of common stock) at a purchase price of $6.881 and stapled warrants to purchase shares of common stock with an exercise price equal to $10.134 per stapled warrant. 

The closing is anticipated to take place on or about September 18, 2025, subject to customary closing conditions.

Honigman represented Helius, led by Corporate Partners Phillip D. Torrence, Michael J. Rosenberg, and N. Danny Shulman, with support from Associates Garrett D. Packer and Sarah E. Meinel.